Part One
Health-Care Solutions from a Distant Shore
Value-Based Competition in India
1.
An Unhealthy Problem Meets an Unlikely Solution
One spring day a few years back, a fifty-something man named George found himself short of breath. His wife drove him to the emergency room at the University of Texas Southwestern Medical Center, where he was diagnosed with pneumonia. When George was released from the hospital four months later, he was presented with a 161-page bill of $474,064 as his share of the costs.
George survived the pneumonia, but he didnât know if he could survive the bill. His room alone cost $73,376, and respiratory services, oxygen, and breathing tests added up to $94,799. âSpecial drugs,â most of which were listed as âSodium Chloride .9%,â otherwise known as IV saline solution, came to $108,663.
George hired a billing advocate, a woman who had worked as a claims processor for Blue Cross Blue Shield until she was sent an astronomical bill for a daughterâs emergency-room visit and decided to go over to the other side. She helped a bit, and the hospital, the president of which was paid $1,244,000 a year, agreed to revise the bill downward to âonlyâ $313,000.
Roughly ten thousand miles away, in a small farming village a couple of daysâ drive from Bangalore, India, an eighteen-month-old boy named Deep was keeping his parents awake with worry. Deep had a heart condition. He was smaller than other children his age, and he didnât have much interest in eating, or in anything else for that matter. But Deepâs parents knew there was hope. They had been in these worry shoes before, five years earlier, when they learned that their daughter would need an operation on her heart. So they took their son to the same hospital, Narayana Health in Bangalore, a private for-profit cardiac hospital that specialized in pediatric heart surgeries, performing sixteen a dayâhalf of its total practice.
Narayana was famous throughout India, not only for its excellent surgical outcomes but for its prices. A typical heart surgery at Narayana cost only about $2,100, tens of thousands of dollars less than the same procedure would cost at hospitals in the United States. More important for families like Deepâs, 60 percent of the pediatric surgeries were provided free or at a discounted price. And yet, Narayana was a profitable company, and in December 2017 had a market valuation of over $1 billion.
Deepâs parents paid just a fraction of the full price for Deepâs heart procedure. âDonât worry about the money,â the hospital told them. âJust take Deep home and see if his appetite improves.â It did, and the boy flourished.
These two stories raise an interesting question: What can all countries, rich and poor, learn from organizations like Narayana Health about how to deliver world-class health care affordably? In the United States, the question is timely, because Americans are at a pivotalâperhaps decisiveâmoment in health-care policy. But the question is relevant in every country. In the United Kingdom, for instance, the National Health Service (NHS) struggles with issues of costs, quality, and access. Jim Mackey, head of its statutory watchdog group, says bluntly: âThe NHS is in a mess.â1 In France, the health-care system is believed to be near bankruptcy.2 And in poor countries, the problem is worse: America and Europe may have millions of people who need better care, but the developing world has billions of people with no care.
It is time to consider some unconventional remedies to the problem, and that is what we attempt in this book. It isnât just hospital leaders, doctors, consultants, and policy makers who should be interested in innovative solutions to the health-care conundrum. We hope this book will also interest insurers; CEOs of companies that spend a fortune on employee benefits; suppliers of drugs, devices, and services to the health-care industry; and entrepreneurs looking to disrupt the industry. We hope there will be more experiments of the kind announced in January 2018 by three big employersâAmazon, Berkshire Hathaway and JPMorgan Chaseâto form an independent company to disrupt health care for their million-plus employees.3 We further hope this book will help mobilize grassroots support for deep and lasting reforms of the health-care sectors in all countries.
Letâs begin by taking a closer look at the situation in the United States.
An Unhealthy Problem
The story of the American health-care system involves the good, the bad, and the ugly. The United States is home to the worldâs best hospitals and the worldâs best doctors, and it has produced more health-care miracles than any other country in the world. Americans and American universities dominate the Nobel Prize in Medicine. US pharmaceutical companies develop new drugs that save countless lives. And US medical-device companies produce a steady stream of innovations. Americans get to choose their doctors and insurers, and they donât have to deal with care rationing or long waiting times for procedures. The care that Deep was lucky to get in India is routinely available to most Americans, if more expensively. Thatâs the good.
Now for the bad and the ugly. In 2016, the United States spent a staggering $3.3 trillion, or almost 17.9 percent of its GDP, on health careâthatâs $10,348 per person, at least twice as much as any other country in the industrialized world spent. Between 2000 and 2015, US health-care costs rose at twice the rate of the Consumer Price Index.4 This has caused health-insurance premiums, copayments, and coinsurance payments to soar for people like George. The collateral damage is widespread. Todayâs health-care costs add an estimated 15 percent to the cost of every American-made automobile. They cannibalize paychecks by diverting company funds to employer-sponsored health plans.5 And they crowd out discretionary government spending in important areas such as infrastructure, research, and education. By 2030, when 20 percent of the US population will be over sixty-five years old, the upward pressure on health-care costs will be unprecedented, and US national and household budgets will be looking for life support.
Despite this record spending, the quality of American health care is uneven, with frequent medical errors, failures, and a great many inefficiencies. A 2017 Commonwealth Fund report on health in eleven industrialized nations ranked the United States first in spending and last in overall health-care performance.6 American life expectancy ranked forty-third in the world, medical errors were the third-leading cause of hospital deaths, and three-quarters of health-care spending was on chronic diseases, many of which could be better managed or even prevented. The thirty-day hospital readmission rate for Medicare patients was a discouraging 15 percent to 16 percent, and it was costing taxpayers $17 billion a year. Access to health care was also spotty: Even after the Affordable Care Act helped twenty million Americans obtain health insurance, twenty-eight million remained uninsured. Underinsurance was also widespread, affecting 23 percent of Americans. And persistent racial, ethnic, and income disparities haunted health-care access and outcomes.7
Reflecting on the state of US health care, the Institute of Medicine concluded in a now famously scathing report: âBetween the health care we have and the care we could have lies not just a gap but a chasm.â8 That was seventeen years ago, and while there has been a lot of talkâseemingly endless talkâabout health-care reform in the intervening years, not all that much has changed.
How can that possibly be true? For one thing, there are many special interests in play. Insurers, regulators, doctorsâ groups, the pharmaceutical industry, workersâ unions, political partiesâall these players have interests to protect, and those interests put a drag on change.
But the real reason the health-care debate hasnât gotten anywhere is that would-be reformers are debating about the wrong things. Itâs not about who pays for what. Skyrocketing health-insurance premiums are just a symptom of the underlying problem. The problem with American health care is that it costs too much, the quality is uneven, and too many people canât get the care they need.
When we look at the problem primarily in this way, as a crisis of health-care delivery and not as an issue of who pays for what, we can begin to see new solutions from unexpected places.
Reverse Innovation in Health-Care Delivery
Reverse innovation refers to the case in which an innovation flows from a poor country to a rich country rather than the other way around. We have been studying this phenomenon for over a decade, and for the past five years we have wrestled specifically with the question of how it might apply to health-care delivery. (See the sidebar âAbout Our Research.â)
What Is Reverse Innovation?
The locus of innovation in the global economy is changing, and so are patterns of dissemination. Poor countries no longer just borrow innovations from developed countries.9 They also contribute innovations to the rest of the world, including developed countries. We call this transfer of new ideas and innovations from poor regions to rich âreverse innovation.â
Innovations arising in poor countries typically involve practices that maximize value (i.e., the ratio of benefits to price), by making products extremely affordable and easy to use, while also keeping quality high. Although these innovations arise from conditions of poverty and scarcity, they can address needs in conditions of wealth and abundance perfectly well.
Reverse innovation can take on many forms. An American multinational corporation could develop a product for its consumers in poor countries and then turn around and sell the product back home, as an entry-level product or to a niche market. For example, General Electric developed an extremely low-cost, portable ultrasound machine in China and later sold it in many countries, including the United States.
Alternatively, an emerging-market firm could develop products tailored to the unique requirements of poor countries and then market such products to rich countries. Reverse innovation can also occur indirectly through knowledge transfer. For instance, an established company or a startup in the United States might be inspired by business models and management innovations adopted in poor countries and could bring those models to the United States, disrupting the industry.
Reverse innovation in health-care delivery is still a nascent phenomenon. It is a ânext practice,â the importance and significance of which will grow in the next decade as the United States and other rich countries confront the challenge of maximizing value by dramatically lowering costs.
Few American hospitals operate internationally, and none has a subsidiary in India. As such, reverse innovation in health care must occur indirectly through knowledge transfer, which requires that leaders of US health-care organizations cultivate a global mindset. Leadership requirements for developing a global mindset include:
- Curiosity about health-care innovations in poor countries;
- Willingness to acquire knowledge about such innovations through immersion experiences in poor countries;
- Ability to modify and adapt such innovations to suit the unique US context.
Reverse innovation first came to our attention in our work with General Electric, a multinational company that took a product developed in China for the Chinese marketâan inexpensive and portable, high-quality ultrasound deviceâand marketed it successfully in the United States. What began as a defensive move to counter Chinese competitors in China became a big hit for GE not only in other emerging markets but also in the United States, particularly in rural and far-flung areas, where the nearest large clinic or hospital was hours away. The low-cost ultrasound also pioneered new applications for situations in which portability was critical or space was constrained, such as at accident sites and in operating suites. We wrote our findings up as a...